首页|Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis:A post hoc analysis of the JADE REGIMEN phase 3 trial

Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis:A post hoc analysis of the JADE REGIMEN phase 3 trial

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据

Hang Li、Hao Cheng、Qianjin Lu、Wei Lai、Xiaohua Tao、Gerardo A.Encinas、Shefali Vyas、Bo Wang、Xin Luo、Shiqi Li

展开 >

Department of Dermatology,Peking University First Hospital,National Clinical Research Center for Skin and Immune Diseases,Beijing 100034,China

Department of Dermatology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang 310016,China

Department of Dermatology,The Second Xiangya Hospital of Central South University,Changsha,Hunan 410011,China

Department of Dermatology,The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong 510630,China

Department of Dermatology,Zhejiang Provincial People's Hospital,Hangzhou Medical College,Hangzhou,Zhejiang 310014,China

Pfizer S.A.de C.V.,Mexico City,Mexico

Pfizer Inc.,New York,NY,USA

Pfizer Investment Co.,Ltd,Beijing 100010,China

Pfizer(China)R&D Co.,Ltd,Shanghai 201200,China

Pfizer PBG,Shanghai 200041,China

展开 >

Pfizer Inc.,New York,NY,USA,in accordance with Good Publication Practice(GPP )guidelines(2022)Pfizer Inc.,New York,NY,USA,in accordance with Good Publication Practice(GPP )guidelines(2022)

Ann Intern Med.202210.7326/M22-1460

2024

10.1097/CM9.0000000000003159

中华医学杂志(英文版)
中华医学会

中华医学杂志(英文版)

CSTPCD
影响因子：0.838
ISSN：0366-6999
年,卷(期)：2024.137(16)